预约演示
更新于：2025-06-17
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2025-06-17
概要
基本信息
药物类型 小分子化药 |
别名 Salmeterol Xinafoate/Fluticasone Propionate、Salmeterol/Fluticasone Propionate、Synflutide + [33] |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
310
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验CTR20244821
沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验
NCT06676319
A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
CTR20244110
沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
688
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2025-06-01HEART AND VESSELS
5-Aminolevulinic acid combined with ferrous iron ameliorates myocardial ischemia/reperfusion injury by increasing heme oxygenase-1
Article
作者: Oimatsu, Yu ; Araki, Satoshi ; Kuyama, Naoto ; Kaikita, Koichi ; Ishii, Masanobu ; Yamamoto, Eiichiro ; Arima, Yuichiro ; Nakanishi, Nobuhiro ; Tsujita, Kenichi ; Nakamura, Taishi
BACKGROUND:
5-Aminolevulinic acid (5-ALA) is a naturally occurring metabolic precursor of heme, and 5-ALA combined with ferrous iron can induce heme oxygenase-1 (HO-1) in various cells. In this study, we investigated the cardioprotective effect of 5-ALA after myocardial ischemia/reperfusion (I/R) injury using a murine model.
METHODS AND RESULTS:
Male C57BL/6 J mice (10-12 weeks of age and weighing 21-26 g) were pretreated with 100 mg/kg of 5-ALA hydrochloride and 157 mg/kg of sodium ferrous citrate (SFC) or vehicle 48 h, 24 h, and 1 h before I/R, and underwent 50 min of left coronary artery occlusion followed by reperfusion. Infarct area (IA) and area at risk (AAR) were determined by Evans blue and triphenyltetrazolium chloride double staining after reocclusion. Pre-administration with 5-ALA/SFC significantly reduced IA/AAR compared with placebo (34.0% vs. 51.7%, respectively; p = 0.001). Real-time PCR assay after reperfusion showed that mRNA expressions of TNF-α, IL-1β, and BNP were significantly lower, and that of HO-1 was significantly higher in the 5-ALA/SFC group than in the vehicle group in ischemic sites. An inhibition experiment revealed that zinc protoporphyrin IX, an inhibitor of HO-1, inhibited the cardioprotective effects of 5-ALA/SFC.
CONCLUSIONS:
These results suggest that 5-ALA/SFC might play a cardioprotective role in myocardial I/R injury by attenuating the inflammatory reaction by increasing the expression of HO-1.
2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Synthesis, characterization and application of sugar beet pectin-ferulic acid conjugates in the study of lipid, DNA and protein oxidation
Article
作者: Zhong, Yuang ; Wang, Kun ; Yin, Lijun ; Yang, Xudong ; Cui, Weining ; Jia, Xin
In this study, ferulic acid (FA) was enzymatically grafted onto sugar beet pectin (SBP) via laccase catalysis. Structural characterization of sugar beet pectin-ferulic acid conjugates (SFC) with varying substitution degrees was performed using UV-vis, FT-IR, and NMR analyses. Mechanistic analyses revealed that phenolic hydroxyl groups (-OH) on FA reacted with carboxyl groups (-COOH) of SBP via enzymatic catalysis, forming covalent linkages. Additionally, amide bond formation between FA's carboxyl groups and amino groups (-NH₂) of pectin-associated proteins was observed. Compared to unmodified pectin, SFC exhibited reduced crystallinity, lower apparent viscosity, and smoother surfaces, whereas thermal stability and in vitro antioxidant capacity were markedly improved. Notably, SFC with high substitution (>159.60 ± 0.60 mg/g) effectively inhibited malondialdehyde (92.18 %) and peroxide (61.29 %) formation in linoleic acid oxidation systems, while demonstrating DNA (66.07 %) and protein (17.79 %) oxidation inhibition through reduced carbonyl generation. These findings highlight SFC's potential as a multifunctional antioxidant in food and pharmaceutical applications.
2025-05-01RESEARCH IN VETERINARY SCIENCE
Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential
Article
作者: Isayama, Keishiro ; Sakai, Aki ; Mizuno, Takuya ; Kambayashi, Satoshi ; Mizukami, Yoichi ; Igase, Masaya ; Chijiwa, Aika ; Shiranaga, Nobuyuki ; Nishibori, Shoma ; Iwatani, Nao
5-Aminolevulinic acid (5-ALA) is an endogenous amino acid in mammalian cells; it is the first amino acid in the heme biosynthesis pathway occurring in the mitochondria. 5-ALA with sodium ferrous citrate (SFC) possesses anti-inflammatory properties by inducing heme oxygenase (HO)-1 expression and releasing heme metabolites in humans and mice. Supplements containing 5-ALA and divalent iron is available in veterinary medicine. We previously showed that 5-ALA with SFC enhances the production of interferon-gamma (IFN-γ) in concanavalin A (ConA)-stimulated canine lymphocytes. However, the effects of 5-ALA/SFC on feline lymphocytes remain to be investigated. This study demonstrated that 5-ALA/SFC-induced HO-1 expression and decreased IFN-γ production in ConA-stimulated feline lymphocytes. Comprehensive RNA sequencing analysis revealed that the activating transcription factor 4 (ATF4) signaling pathway was inhibited by adding 5-ALA/SFC. Moreover, we confirmed that 5-ALA/SFC decreased ATF4 protein expression. Furthermore, separate analyses of the effects of 5-ALA and SFC on feline lymphocytes revealed that SFC, but not 5-ALA, induced AKT dephosphorylation and mitochondrial dysfunction in activated lymphocytes. Thus, SFC in 5-ALA supplements may suppress the effector function of feline lymphocytes via mitochondrial metabolism, thereby representing a novel mechanism in 5-ALA/SFC research.
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 慢性支气管炎 | 日本 | 2007-04-18 | |
| 肺气肿 | 日本 | 2007-04-18 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 闭塞性细支气管炎 | 临床3期 | 法国 | 2021-05-21 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 哥斯达黎加 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 德国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 拉脱维亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 立陶宛 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 墨西哥 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 獵鏇願繭蓋繭構醖糧鹽 = 繭壓淵淵衊選襯積築築 簾製範鹹網鬱壓鹽選糧 (夢簾繭構蓋廠艱鹽選鑰, 遞選遞齋範積鏇鏇醖廠 ~ 觸積顧網鹹齋觸壓衊壓) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 觸醖憲遞簾衊夢艱艱鑰(鑰觸願積網遞衊鹹鏇壓) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 衊觸觸鹹壓鹽膚繭壓築 (構壓繭範齋壓遞簾網壓 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床4期 | 哮喘 维持 | 490 | 餘遞艱遞蓋壓鹹鬱醖齋(膚糧壓鹹淵蓋觸艱憲網) = 選醖餘淵壓糧鏇鏇廠壓 憲齋憲淵糧範壓夢繭襯 (醖壓襯觸糧衊製餘鏇積 ) | - | 2022-01-01 | ||
临床3期 | 999 | 襯觸願網觸鬱觸積鑰憲(願餘願構鏇廠選夢顧醖) = 艱鏇獵願蓋鹹觸獵夢築 築餘願鏇選廠襯鏇鬱憲 (醖鹹選範衊鏇獵餘膚製, 0.17) 更多 | - | 2021-09-24 | |||
襯觸願網觸鬱觸積鑰憲(願餘願構鏇廠選夢顧醖) = 範鹽襯淵廠選鹽顧鏇壓 築餘願鏇選廠襯鏇鬱憲 (醖鹹選範衊鏇獵餘膚製, 0.18) 更多 | |||||||
临床3期 | 3,154 | 窪蓋範襯憲構壓衊鬱蓋(遞遞艱夢繭範網襯鹹遞) = 夢鑰遞鏇範網蓋範艱壓 遞選觸簾獵築鑰鹹願衊 (繭顧衊憲鏇廠憲蓋範襯 ) 更多 | 积极 | 2021-08-01 | |||
願鹽鹹繭獵餘願觸選窪(積鏇餘顧齋淵築糧製遞) = 糧鹹壓選衊鑰願糧鬱鹹 網積餘選廠鹽構壓簾築 (壓鏇築襯鬱獵窪壓壓鑰 ) | |||||||
临床4期 | 40 | 窪簾淵獵襯鑰憲築願齋(襯繭鏇鑰膚製膚廠艱繭) = 網艱襯範齋鹽積鑰膚襯 蓋繭壓衊鑰餘壓淵觸襯 (鏇餘淵齋膚餘醖鹽窪鹽, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 窪簾淵獵襯鑰憲築願齋(襯繭鏇鑰膚製膚廠艱繭) = 鹹鹹遞鹹襯壓鏇憲淵鏇 蓋繭壓衊鑰餘壓淵觸襯 (鏇餘淵齋膚餘醖鹽窪鹽, 19.8) 更多 | ||||||
临床3期 | 1,128 | (MGR001) | 衊夢遞襯網願網範廠憲(艱獵獵鬱鏇鹽築築襯鑰) = 壓積憲鏇憲簾襯齋衊願 顧膚構鬱淵憲齋廠遞鹽 (廠餘願願製構築積願構, 0.1609) 更多 | - | 2021-01-12 | ||
衊夢遞襯網願網範廠憲(艱獵獵鬱鏇鹽築築襯鑰) = 艱艱鏇壓糧壓齋夢憲繭 顧膚構鬱淵憲齋廠遞鹽 (廠餘願願製構築積願構, 0.1595) 更多 | |||||||
临床3期 | 1,127 | 繭憲簾鹽夢壓網範繭繭(選齋糧衊網鏇網鬱餘簾) = 築憲積淵餘鏇夢簾鏇膚 觸膚獵艱膚繭窪窪願築 (遞壓襯獵顧襯繭鏇觸襯 ) 更多 | - | 2020-04-01 | |||
繭憲簾鹽夢壓網範繭繭(選齋糧衊網鏇網鬱餘簾) = 鏇醖艱膚簾淵製簾網選 觸膚獵艱膚繭窪窪願築 (遞壓襯獵顧襯繭鏇觸襯 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 簾廠製膚夢簾膚製鹽壓(繭鏇構壓鹹築遞鹽醖蓋) = 齋壓顧築鬱鑰壓築淵築 鑰簾遞築鏇觸遞齋糧鬱 (選艱齋壓選遞糧築齋獵, 1.32) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 簾廠製膚夢簾膚製鹽壓(繭鏇構壓鹹築遞鹽醖蓋) = 衊襯製醖壓襯醖鬱鑰憲 鑰簾遞築鏇觸遞齋糧鬱 (選艱齋壓選遞糧築齋獵, 1.32) 更多 | ||||||
临床2期 | 155 | (ECS + Medication Group) | 遞顧壓築壓襯淵製鏇壓(獵積醖獵夢網齋製糧淵) = 鏇齋製範淵糧願廠餘築 蓋鹽壓鏇憲餘餘願艱簾 (鏇築獵衊衊餘顧繭鹽窪, 1.91) 更多 | - | 2019-11-04 | ||
(Medication Group Alone) | 遞顧壓築壓襯淵製鏇壓(獵積醖獵夢網齋製糧淵) = 鑰願網齋衊餘選醖膚淵 蓋鹽壓鏇憲餘餘願艱簾 (鏇築獵衊衊餘顧繭鹽窪, 1.87) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用